Development of a SARS-CoV-2 vaccine for the elderly by engineering virus-like particles with SARS-CoV-2 antigen and membrane-anchored cytokines

Metaclipse Therapeutics Corporation, Atlanta GA

Investigators

Abstract

Vaccine design using SARS-CoV-2 spike protein on VLPs which contain GM-CSF and IL-12 (targeting elderly). There is data supporting the premise that including GM-CSF and IL-12 in the VLP can overcome poor immune responses in elderly. Animal testing will begin using VLP with antigen and cytokines, this process will be optimized for GMP and scale-up.